SPOTFIRE VG Control Panel M534, SPOTFIRE VG Negative Control
Maine Molecular Quality Controls, Inc. · Decision date Oct 21, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-21 for K262573, a traditional 510(k) submitted 07/27/2026 by Maine Molecular Quality Controls, Inc. of Saco, Maine. The device is listed as SPOTFIRE VG Control Panel M534 and SPOTFIRE VG Negative Control, under the classification name Assayed External Control Material For Microbiology Nucleic Acid Amplification (NAT) Assays, regulation 866.3920, product code PMN, in the Microbiology specialty and review panel.
SESE means the submission was cleared to market; it is not a PMA approval. The record shows no third-party review, no combination product status and no authorized predetermined change control plan. The public record does not include the substantial-equivalence basis, the predicate device, the control panel's target analytes, or performance data, so the specific components and any changed items cannot be described from this source.
The page was last updated 11/02/2026. No clinical or analytical performance conclusions are drawn here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 21, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262573
- Regulatory pathway
- 510(k) premarket notification
- Product code
- PMN
- Decision code
- SESE
- Decision date
- Oct 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays.
- Product code
- PMN
- FDA device class
- 2
FDA decision timeline
K262573 received
Application receipt date recorded by FDA.
K262573 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code PMN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| BioFire Defense, LLC | 510(k) clearance | Nov 4, 2026 | FDA | |
| Maine Molecular Quality Controls, Inc. | 510(k) clearance | Oct 30, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Maine Molecular Quality Controls, Inc.
- Headquarters
- Not reported
- Brand website
- mmqci.com
- FDA applicant address
- Saco, ME
Sources and methodology
- Original FDA record: K262573
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
